Crossover Study From Macitentan or Bosentan Over to Ambrisentan

Summary

The purpose of this study is to learn more about the safety and effects of switching treatments from bosentan (Tracleer) or macientan (Opsumit) to ambrisentan (Letairis) over 24 weeks in subjects with Connective Tissue Disease associated Pulmonary Arterial Hypertension (CTD-PAH).

Timeline

Start

2016-06

Primary completion

2017-07-07

Completion

2017-07-07

Drugs

Indications